1. Home
  2. MOH vs TGTX Comparison

MOH vs TGTX Comparison

Compare MOH & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Molina Healthcare Inc

MOH

Molina Healthcare Inc

N/A

Current Price

$196.74

Market Cap

10.5B

Sector

Health Care

ML Signal

N/A

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

N/A

Current Price

$55.20

Market Cap

8.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MOH
TGTX
Founded
1980
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5B
8.5B
IPO Year
2002
2008

Fundamental Metrics

Financial Performance
Metric
MOH
TGTX
Price
$196.74
$55.20
Analyst Decision
Hold
Buy
Analyst Count
19
8
Target Price
★ $209.12
$69.71
AVG Volume (30 Days)
547.3K
★ 1.6M
Earning Date
10-21-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 1746.67
EPS
★ 1.46
0.17
Revenue
★ $45,426,000,000.00
$2,785,000.00
Revenue This Year
$2.05
$55.81
Revenue Next Year
$8.06
$37.36
P/E Ratio
★ $134.14
$313.76
Revenue Growth
★ 11.75
N/A
52 Week Low
$121.06
$26.76
52 Week High
$244.89
$59.30

Technical Indicators

Market Signals
Indicator
MOH
TGTX
Relative Strength Index (RSI) 51.77 51.25
Support Level $196.50 $51.76
Resistance Level $204.11 $58.26
Average True Range (ATR) 6.54 2.04
MACD 0.88 -0.36
Stochastic Oscillator 73.00 49.73

Price Performance

Historical Comparison
MOH
TGTX

About MOH Molina Healthcare Inc

Molina Healthcare Inc provides medical insurance plans through Medicaid, the individual exchanges, and Medicare. The company operates in four reportable segments consisting of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. It manages health benefit risks for more than 5 million people, with more than 85% of those members coming through contracts with state governments for their Medicaid programs. Medicaid contracts in four states-California, New York, Texas, and Washington-account for over half of its enrollees.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: